These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 23062567)

  • 1. Adiposopathy, diabetes mellitus, and primary prevention of atherosclerotic coronary artery disease: treating "sick fat" through improving fat function with antidiabetes therapies.
    Bays HE
    Am J Cardiol; 2012 Nov; 110(9 Suppl):4B-12B. PubMed ID: 23062567
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adiposopathy is "sick fat" a cardiovascular disease?
    Bays HE
    J Am Coll Cardiol; 2011 Jun; 57(25):2461-73. PubMed ID: 21679848
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Obesity, adiposity, and dyslipidemia: a consensus statement from the National Lipid Association.
    Bays HE; Toth PP; Kris-Etherton PM; Abate N; Aronne LJ; Brown WV; Gonzalez-Campoy JM; Jones SR; Kumar R; La Forge R; Samuel VT
    J Clin Lipidol; 2013; 7(4):304-83. PubMed ID: 23890517
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiovascular implications of antihyperglycemic therapies for type 2 diabetes.
    Ovalle F
    Clin Ther; 2011 Apr; 33(4):393-407. PubMed ID: 21635987
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diabetes and obesity: therapeutic targeting and risk reduction - a complex interplay.
    Niswender K
    Diabetes Obes Metab; 2010 Apr; 12(4):267-87. PubMed ID: 20380648
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early and intensive therapy for management of hyperglycemia and cardiovascular risk factors in patients with type 2 diabetes.
    Dailey G
    Clin Ther; 2011 Jun; 33(6):665-78. PubMed ID: 21704233
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardiovascular risk factors in a patient with diabetes mellitus and coronary artery disease: therapeutic approaches to improve outcomes: perspectives of a preventive cardiologist.
    Davidson MH
    Am J Cardiol; 2012 Nov; 110(9 Suppl):43B-49B. PubMed ID: 23062566
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adiposopathy: how do diet, exercise and weight loss drug therapies improve metabolic disease in overweight patients?
    Bays H; Blonde L; Rosenson R
    Expert Rev Cardiovasc Ther; 2006 Nov; 4(6):871-95. PubMed ID: 17173503
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early insulin treatment to prevent cardiovascular disease in prediabetes and overt diabetes.
    Roman G; Hancu N
    Horm Metab Res; 2009 Feb; 41(2):116-22. PubMed ID: 19214921
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Treatment of patients with diabetes mellitus type 2 and coronary artery disease].
    Wiersma JJ; Trip MD; Piek JJ
    Ned Tijdschr Geneeskd; 2006 Feb; 150(7):361-6. PubMed ID: 16523798
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lorcaserin and adiposopathy: 5-HT2c agonism as a treatment for 'sick fat' and metabolic disease.
    Bays HE
    Expert Rev Cardiovasc Ther; 2009 Nov; 7(11):1429-45. PubMed ID: 19900026
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diabetes mellitus: a cardiovascular disease.
    Candido R; Srivastava P; Cooper ME; Burrell LM
    Curr Opin Investig Drugs; 2003 Sep; 4(9):1088-94. PubMed ID: 14582453
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treating the diabetic patient: appropriate care for glycemic control and cardiovascular disease risk factors.
    Zarich SW
    Rev Cardiovasc Med; 2003; 4 Suppl 6():S19-28. PubMed ID: 14668700
    [TBL] [Abstract][Full Text] [Related]  

  • 14. From hyperglycemia to the risk of cardiovascular disease.
    Leiter LA
    Rev Cardiovasc Med; 2006; 7 Suppl 2():S3-9. PubMed ID: 17224875
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [What should be the target of therapy in the adult-onset diabetes mellitus?].
    Yki-Järvinen H
    Duodecim; 1999; 115(10):1119-20. PubMed ID: 11877850
    [No Abstract]   [Full Text] [Related]  

  • 16. Current antihyperglycemic treatment strategies for patients with type 2 diabetes mellitus.
    Blonde L
    Cleve Clin J Med; 2009 Dec; 76 Suppl 5():S4-11. PubMed ID: 19952303
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The proinflammatory and hypercoagulable state of diabetes mellitus.
    Aras R; Sowers JR; Arora R
    Rev Cardiovasc Med; 2005; 6(2):84-97. PubMed ID: 15976731
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reducing cardiovascular complications of type 2 diabetes by targeting multiple risk factors.
    Reasner CA
    J Cardiovasc Pharmacol; 2008 Aug; 52(2):136-44. PubMed ID: 18670366
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic potential of aleglitazar, a new dual PPAR-α/γ agonist: implications for cardiovascular disease in patients with diabetes mellitus.
    Cavender MA; Lincoff AM
    Am J Cardiovasc Drugs; 2010; 10(4):209-16. PubMed ID: 20653327
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Weight management for type 2 diabetes mellitus: global cardiovascular risk reduction.
    Lee M; Aronne LJ
    Am J Cardiol; 2007 Feb; 99(4A):68B-79B. PubMed ID: 17307059
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.